Portal de Periódicos da CAPES

FGF20 and Parkinson's disease: No evidence of association or pathogenicity via α‐synuclein expression

2009; Wiley; Volume: 24; Issue: 3 Linguagem: Inglês

10.1002/mds.22442

1531-8257

Christian Wider, Justus C. Dächsel, Alexandra I. Soto, Michael G. Heckman, Nancy N. Diehl, Mei Yue, Sarah Lincoln, Jan Aasly, Kristoffer Haugarvoll, John Q. Trojanowski, Spiridon Papapetropoulos, Deborah C. Mash, Alex Rajput, Ali H. Rajput, J. Mark Gibson, Timothy Lynch, Dennis W. Dickson, Ryan J. Uitti, Zbigniew K. Wszołek, Matthew J. Farrer, Owen A. Ross,

Restless Legs Syndrome Research

Genetic variation in fibroblast growth factor 20 (FGF20) has been associated with risk of Parkinson's disease (PD). Functional evidence suggested the T allele of one SNP, rs12720208 C/T, altered PD risk by increasing FGF20 and alpha-synuclein protein levels. Herein we report our association study of FGF20 and PD risk in four patient-control series (total: 1,262 patients and 1,881 controls), and measurements of FGF20 and alpha-synuclein protein levels in brain samples (nine patients). We found no evidence of association between FGF20 variability and PD risk, and no relationship between the rs12720208 genotype, FGF20 and alpha-synuclein protein levels.